Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 1, 1998, Pages 28-36

  Wolff, M ^a,a   Shafran, S D ^a   Potgieter, P D ^a   Laloo, V G ^a   Irusen, E M ^a   Cassim, I M ^a   Garber, G E ^a   Louie, T J ^a   San Juan, J A ^a   Nogueras, C ^a   Street, M ^a   Bleichner, G ^a   Sollet, J P ^a   Gibert, C ^a   Calvat, S ^a   Giunta, F ^a   Corsini, V ^a   Lipman, J ^a   Hedstrom S A ^a   Juhlin Dannfelt, M ^a   Borulf, B ^a   Edbrooke, D ^a   Holmdahl, T ^a   Grossman, R F ^a   Laaban, J P ^a   Rabbat, A ^a   Lindblom, A ^a   Ahlgren, I ^a   Clara, L ^a   Barcam, L ^a   Coste, F ^a   Dreyfuss, D ^a   Le Bourdelles, G ^a   Dumoulin, J L ^a   Cahn, P E ^a   Muchico, M ^a   Farias, A ^a   Rivas, H ^a   Miller, A ^a   Pagni, E ^a   Paradisi, F ^a   Van Der Linden, C J ^a   Carbon, C ^a   Falissard, B ^a   Geddes, A M ^a   Verhoef, J ^a   Wilson, W R ^a   more..

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFPIROME; CEFTAZIDIME;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT PLANNING;

EID: 6844241938     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.1.28     Document Type: Article

References (27)

1. Alvarez-Lerma, F., and ICU-Acquired Pneumonia Study Group. 1996. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 22:387-394.
2. Anonymous. 1996. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. A consensus statement. Am. J. Respir. Crit. Care Med. 153:1711-1725.
3. Bellido, F., J. C. Pechere, and R. E. W. Hancock. 1991. Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells. Antimicrob. Agents Chemother. 35:68-72.
4. Bergogne-Berezin, E., and E. Vallee. 1994. Pharmacokinetics of antibiotics in respiratory issues and fluids, p. 715-740. In J. E. Pennington (ed.), Respiratory infections: diagnosis and management, 3rd ed. Raven Press, Ltd., New York, N.Y.
5. Brewer, S. C., R. G. Wunderink, C. B. Jones, and K. V. Leeper. 1996. Clinical investigations in critical care: ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109:1019-1029.
6. Bryskier, A., J. Aszodi, and J.-F. Chantot. 1994. Parenteral cephalosporin classification. Expert Opin. Invest. Drugs 3:145-171.
7. Cometta, A., J. D. Baumgartner, D. Lew, W. Zimmerli, D. Pittet, P. Chopart, U. Schaad, C. Herter, P. Eggimann, O. Huber, B. Ricou, P. Suter, R. Auckenthaler, R. Chiolero, J. Bille, C. Scheidegger, R. Frei, and M. P. Glauser. 1994. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob. Agents Chemother. 38:1309-1313.
8. Craven, D. E., and K. A. Steger. 1995. Epidemiology of nosocomial pneumonia. New perspectives of an old disease. Chest 108:1S-16S.
9. Fagon, J.-Y., J. Chastre, A. Vuagnat, J.-L. Trouillet, A. Novara, and C. Gibert. 1996. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 275:866-869.
10. Fagon, J.-Y., J. Chastre, Y. Domart, J.-L. Trouillet, J. Pierre, C. Darne, and C. Gibert. 1989. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am. Rev. Respir. Dis. 139:877-884.
11. Fink, M. P., D. R. Snydman, M. S. Niederman, K. V. Leeper, Jr., R. H. Johnson, S. O. Heard, R. G. Wunderink, J. W. Caldwell, J. J. Shentag, G. A. Siami, R. L. Zameck, D. C. Haverstock, H. H. Reinhart, R. M. Echols, and the Severe Pneumonia Study Group. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 38:547-557.
12. Hilf, M., V. L. Yu, J. Sharp, J. J. Zuravleff, J. A. Korvick, and R. R. Muder. 1989. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am. J. Med. 87:540-546.
13. Jones, R. N., M. A. Pfaller, S. D. Allen, E. H. Gerlach, P. C. Fuchs, and K. E. Aldridge. 1991. Antimicrobial activity of cefpirome: an update compared to third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers. Diagn. Microbiol. Infect. Dis. 14:361-364.
14. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
15. Korvick, J. E., C. S. Bryan, B. Farber, T. R. Beam, Jr., L. Schenfeld, R. R. Muder, D. Weinbaum, R. Lumish, D. N. Gerding, M. M. Wagener, and V. L. Yu. 1992. Prospective study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob. Agents Chemother. 36:2639-2644.
16. Le Gall, J. R., P. Loirat, A. Alperovitch, P. Glaser, C. Granthil, D. Mathieu, P. Mercier, R. Thomas, and D. Villers. 1984. A simplified acute physiology score for ICU patients. Crit. Care Med. 12:975-977.
17. Le Gall, J. R. 1990. Les facteurs pronostiques des maladies infectieuses en réanimation. Lett. Infect. 5:185-190.
18. Leroy, O., H. Georges, C. Beuscart, B. Guery, C. Coffinier, C. Vandenbussche, D. Thevenin, and G. Beaucaire. 1996. Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score. Intensive Care Med. 22:1307-1314.
19. Niederman, M. S., A. Torres, and W. Summer. 1994. Invasive diagnosis testing is not needed routinely to manage suspected ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 150:565-569.
20. Nikaido, H., W. Liu, and E. Y. Rosenberg. 1990. Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob. Agents Chemother. 34:337-342.
21. Norrby, S. R., R. G. Finch, M. Glauser, and an European Study Group. 1993. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. J. Antimicrob. Chemother. 31:927-937.
22. Norrby, S. R., and A. M. Geddes. 1993. Efficacy of cefpirome in the treatment of septicaemia. Scand. J. Infect. Dis. 91:S51-S59.
23. Papazian, L., F. Bregeon, X. Thirion, R. Gregoire, P. Saux, J.-P. Denis, G. Perrin, J. Charrel, J.-F. Dumon, J.-P. Affray, and F. Gouin. 1996. Effect of ventilator-associated pneumonia on mortality and morbidity. Am. J. Respir. Crit. Care Med. 154:91-97.
24. Rello, J., V. Ausina, M. Ricart, J. Castella, and G. Prats. 1993. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 104:1230-1235.
25. Rubinstein, E., H. Lode, C. Grassi, and an Antibiotic Study Group. 1995. Ceftazidime monotherapy vs ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Clin. Infect. Dis. 20:1217-1228.
26. Vincent, J.-L., D. J. Bihari, P. M. Suter, H. A. Bruining, J. White, M. H. Nicolas-Chanoine, M. Wolff, R. C. Spencer, M. Hemmer for the EPIC International Advisory Committee. 1995. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. JAMA 274:639-644.
27. Wolff, M., C. Carbon, B. Falissard, A. Geddes, J. Verhoef, and W. Wilson. 1996. Comparative study of cefpirome (CPO) and ceftazidime (CAZ) in ICU patients with pneumonia, abstr. LM21, p. 284. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.